SI3541387T1 - Odmerek in režim za zaviralce interakcije HDM2-P53 - Google Patents

Odmerek in režim za zaviralce interakcije HDM2-P53

Info

Publication number
SI3541387T1
SI3541387T1 SI201730843T SI201730843T SI3541387T1 SI 3541387 T1 SI3541387 T1 SI 3541387T1 SI 201730843 T SI201730843 T SI 201730843T SI 201730843 T SI201730843 T SI 201730843T SI 3541387 T1 SI3541387 T1 SI 3541387T1
Authority
SI
Slovenia
Prior art keywords
hdm2
regimen
dose
interaction inhibitors
inhibitors
Prior art date
Application number
SI201730843T
Other languages
English (en)
Inventor
Stephane Ferretti
Nelson Guerreiro
Sebastien Jeay
Astrid Jullion
Christophe Meille
Jens Wuerthner
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60452703&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3541387(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SI3541387T1 publication Critical patent/SI3541387T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI201730843T 2016-11-15 2017-11-14 Odmerek in režim za zaviralce interakcije HDM2-P53 SI3541387T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662422144P 2016-11-15 2016-11-15
US201762479391P 2017-03-31 2017-03-31
PCT/IB2017/057097 WO2018092020A1 (en) 2016-11-15 2017-11-14 Dose and regimen for hdm2-p53 interaction inhibitors
EP17804304.8A EP3541387B1 (en) 2016-11-15 2017-11-14 Dose and regimen for hdm2-p53 interaction inhibitors

Publications (1)

Publication Number Publication Date
SI3541387T1 true SI3541387T1 (sl) 2021-08-31

Family

ID=60452703

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201730843T SI3541387T1 (sl) 2016-11-15 2017-11-14 Odmerek in režim za zaviralce interakcije HDM2-P53

Country Status (18)

Country Link
US (1) US10966978B2 (sl)
EP (1) EP3541387B1 (sl)
JP (1) JP6890659B2 (sl)
KR (1) KR102325778B1 (sl)
CN (2) CN115252786A (sl)
AU (1) AU2017362040C1 (sl)
CA (1) CA3043004A1 (sl)
DK (1) DK3541387T3 (sl)
ES (1) ES2880149T3 (sl)
HU (1) HUE055509T2 (sl)
IL (1) IL266171B (sl)
MX (1) MX2019005623A (sl)
PL (1) PL3541387T3 (sl)
PT (1) PT3541387T (sl)
RU (1) RU2762573C2 (sl)
SI (1) SI3541387T1 (sl)
TW (1) TWI757367B (sl)
WO (1) WO2018092020A1 (sl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
CA3043004A1 (en) 2016-11-15 2018-05-24 Novartis Ag Dose and regimen for hdm2-p53 interaction inhibitors
EP3600326B1 (en) * 2017-03-31 2023-01-25 Novartis AG Dose and regimen for an hdm2-p53 interaction inhibitor in hematological tumors
US11091522B2 (en) 2018-07-23 2021-08-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CN110963958A (zh) * 2018-09-30 2020-04-07 上海长森药业有限公司 一种mdm2抑制剂，及其制备方法、药物组合物和应用
JP2022505884A (ja) * 2018-10-30 2022-01-14 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド ｐ５３ＷＴ腫瘍の処置の方法
KR20210106484A (ko) * 2018-12-20 2021-08-30 노파르티스 아게 Hdm2-p53 상호작용 억제제와 bcl2 억제제의 조합 및 암 치료를 위한 이의 용도
WO2021066443A1 (ko) * 2019-09-30 2021-04-08 한미약품 주식회사 Flt3 저해제 및 mdm2 저해제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물
WO2021211819A1 (en) * 2020-04-16 2021-10-21 Albert Einstein College Of Medicine Inhibition of bax-mediated cell death by eltrombopag

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548531B2 (en) 2001-02-09 2003-04-15 Hoffmann-La Roche Inc. Method for cancer therapy
US20030139373A1 (en) 2001-11-20 2003-07-24 Breimer Lars Holger Method for cancer therapy
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
UY33725A (es) 2010-11-12 2012-06-29 Sanofi Sa Antagonistas de mdm2 de espiro-oxindol
US9062071B2 (en) * 2011-12-21 2015-06-23 Merck Sharp & Dohme Corp. Substituted piperidines as HDM2 inhibitors
UY34591A (es) * 2012-01-26 2013-09-02 Novartis Ag Compuestos de imidazopirrolidinona
US20130245089A1 (en) 2012-03-19 2013-09-19 Hoffmann-La Roche Inc. Method for administration
SI3077004T1 (sl) 2013-12-05 2020-07-31 F. Hoffmann-La Roche Ag Novo kombinirano zdravilo za akutno mieloično levkemijo (AML)
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
CA2981753A1 (en) 2015-02-06 2016-08-11 Unity Biotechnology, Inc. Compounds and uses in treatment of senescence-associated conditions
RU2018108804A (ru) 2015-08-14 2019-09-16 Новартис Аг Фармацевтические комбинации и их применение
CA3043004A1 (en) 2016-11-15 2018-05-24 Novartis Ag Dose and regimen for hdm2-p53 interaction inhibitors
EP3600326B1 (en) 2017-03-31 2023-01-25 Novartis AG Dose and regimen for an hdm2-p53 interaction inhibitor in hematological tumors

Also Published As

Publication number Publication date
KR102325778B1 (ko) 2021-11-12
HUE055509T2 (hu) 2021-12-28
RU2762573C2 (ru) 2021-12-21
PT3541387T (pt) 2021-07-14
RU2019118261A3 (sl) 2021-03-18
DK3541387T3 (da) 2021-07-19
US10966978B2 (en) 2021-04-06
RU2019118261A (ru) 2020-12-17
MX2019005623A (es) 2019-08-14
JP6890659B2 (ja) 2021-06-18
IL266171A (en) 2019-06-30
PL3541387T3 (pl) 2021-10-25
CA3043004A1 (en) 2018-05-24
EP3541387B1 (en) 2021-04-21
IL266171B (en) 2021-12-01
CN109982702A (zh) 2019-07-05
JP2020500190A (ja) 2020-01-09
AU2017362040A1 (en) 2019-05-02
WO2018092020A1 (en) 2018-05-24
ES2880149T3 (es) 2021-11-23
US20190298719A1 (en) 2019-10-03
TWI757367B (zh) 2022-03-11
TW201822817A (zh) 2018-07-01
CN115252786A (zh) 2022-11-01
EP3541387A1 (en) 2019-09-25
AU2017362040B2 (en) 2020-04-30
AU2017362040C1 (en) 2020-09-10
KR20190084292A (ko) 2019-07-16

Similar Documents

Publication Publication Date Title
IL269462B (en) mdm2 inhibitors and therapeutic methods using them
ME03759B (me) Inhibitori bromodomena
HK1243326A1 (zh) 溴結構域抑制劑
IL266171B (en) Dosage and therapeutic regimen for hdm2-p53 interaction inhibitors
HK1243072A1 (zh) 布羅莫結構域抑制劑及其用途
ZA201801747B (en) Medication packaging and dose regimen system
HK1243415A1 (zh) 溴結構域抑制劑
ZA201705591B (en) Medication packaging and dose regimen system
GB201713653D0 (en) Dosage regimen
HK1245153A1 (zh) Btk抑制劑組合和給藥方案
IL255530A (en) Efflux-pump inhibitors and therapeutic uses thereof
IL268993A (en) Dosage and therapeutic regimen for hdm2-p53 interaction inhibitors in hematologic tumors
GB201521217D0 (en) Dosage regimens
IL247084B (en) dose fgh–18
GB201418710D0 (en) Dosage regimen
PL3250089T3 (pl) Urządzenie do wielokrotnego dozowania i magazynek
IL266255A (en) New dosage regimen
GB2544278B (en) Syringes and inserts for syringes
HK1216970A2 (zh) 種行李箱包角裝置及行李箱
ZA201807614B (en) Bromodomain inhibitors
GB201617850D0 (en) Dosage regimen
GB201610502D0 (en) Dosage regimen
GB201521216D0 (en) Dosage regimen
GB201418708D0 (en) Dosage regimen
GB201411345D0 (en) Nicotine dosage regimen